Medical Education Grant: Multiple Myeloma
At Johnson & Johnson, we’re building a more inclusive and connected health system by supporting independent training and education initiatives. We are proud to provide grants that support eligible organizations in offering independent continuing medical education for healthcare professionals – including physicians, nurses, residents, and pharmacists – by enhancing their skills and knowledge in meeting the needs of patients and the community.
Requests for educational grants are evaluated consistent with appropriate internal and external guidelines and policies. We prioritize support in areas of therapeutic interest, and are particularly interested in initiatives that support communities facing barriers to equitable healthcare access and representation.
- Newly Diagnosed
- Transplant eligible/ineligible NDMM
- Maintenance therapy
- Understanding the role of MRD in defining or adapting duration of therapy
- High Risk patients, including elderly and minority patients
- Defining roles of Triplet & Quad based therapy
Relapsed Refractory
- MOA and clinical use of BCMA & GPRC5D targeting bispecific antibodies (BsAbs)
- Novel combinations of bispecific antibodies
- Bridging therapy for CAR-T
- Sequencing of BCMA and GPRC5D, and of bispecifics and CAR-T
- Optimal therapy for patient groups (high risk, elderly, etc)
- Integration of BsAbs into practice
- RWE
- In patient/out-patient strategies for step up dosing
- Patient selection
- AE mitigation and management
- On target off tumor AE’s
- Care Coordination (Academic/Community HCPs)
- Outpatient Administration & Remote Monitoring
Funding decisions:
Following an internal review process, you will be notified of the status of your application within 90 days of a completed submission and no additional information is required.
Delivery Methods:
Delivery methods vary per therapeutic area. They may include live and virtual activities, dinner programs, grand rounds, and on-site engagements with healthcare teams, ensuring our grants reach diverse audiences within the healthcare community.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.